Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pegcyte
- Development stage
- Unknown
- Lead developer
- Nanogen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Pegcyte is a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) developed by Nanogen Pharmaceutical Biotechnology. As a long-acting analog of filgrastim, it consists of filgrastim covalently linked to a polyethylene glycol (PEG) molecule, which significantly extends its half-life and reduces the frequency of administration. Pegcyte acts by binding to the G-CSF receptor (CSF3R) on hematopoietic cells, stimulating the proliferation, differentiation, and activation of neutrophils. This mechanism effectively reduces the duration and severity of neutropenia in patients undergoing myelosuppressive chemotherapy. It was developed as a biosimilar to the reference product Neulasta and is primarily indicated for the prevention of chemotherapy-induced neutropenia in patients with non-myeloid malignancies.
- Brand names
- Pegcyte
- Other names
- pegfilgrastimNanogen pegfilgrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on Pegcyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pegcyte.